RGEN – repligen corporation (US:NASDAQ)

News

Repligen Corporation to Present at Upcoming Investor Conferences
Repligen to Report Third Quarter 2024 Financial Results
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release [Yahoo! Finance]
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More [Yahoo! Finance]
Repligen Co. (NASDAQ: RGEN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $205.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com